Clinical trials
Ovarian Carcinoma clinical trials
Below are recruiting ovarian carcinoma clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT04811703RecruitingPhase 1
Testing aerosol chemotherapy through the belly for advanced ovarian cancer
This Phase 1 study tests a new way to deliver chemotherapy inside the abdomen (belly) using a pressurized aerosol during a procedure, along with standard blood (IV) chemotherapy. It may help people with advanced ovarian cancer whose tumors have not progressed but are not removable with surgery yet.
LilleAges 18–75 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04878094RecruitingPhase 3
Test dye imaging during surgery for ovarian cancer
This study tests whether using a special imaging dye during surgery can help surgeons better manage parts of the bowel during operations for ovarian cancer. It may help guide whether a low anterior rectosigmoid resection and reconnection (anastomosis) are needed.
Basking Ridge, New JerseyAges Any age - NCT05773859RecruitingPhase 1/Phase 2
Vaccination before surgery to treat advanced ovarian cancer
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Nijmegen, GelderlandAges 18 years+ - NCT03296826Recruiting
Study for women with BRCA gene changes
This study follows women who carry BRCA1 or BRCA2 gene variants (or a gene variant of unclear meaning) to learn about their risks over time. It may help improve how genetic information is used to guide future care.
OkayamaAges 20 years+ - NCT06065462RecruitingPhase 1/Phase 2
Dostarlimab and LB-100 for clear cell ovarian cancer
This trial tests a combination of two drugs—dostarlimab (an immunotherapy) and LB-100 (a new drug targeting a protein called PP2A)—for people with clear cell ovarian cancer that has returned or is resistant to platinum chemotherapy. The goal is to see if this combination is safe and effective for this specific type of cancer.
Houston, TexasAges 18 years+ - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT02073500Recruiting
Study of treatments and models for cancer in the belly lining
This study looks at how cancers that spread along the belly lining (“peritoneal surface malignancies”) behave and how different treatment strategies may work. It may help improve how doctors select and test treatments for people who are candidates for CRS-HIPEC, a specific cancer surgery approach.
OsloAges 18 years+ - NCT07540403Recruiting
Study of ovarian cancer outcomes in treatment-resistant cases
This research study follows patients with epithelial ovarian cancer that has returned or worsened quickly after treatment (within 6 months). The goal is to understand survival patterns and outcomes in these difficult-to-treat cases to potentially improve future care.
RomeAges 18 years+ - NCT04834544RecruitingPhase 2
Maintenance vaccine treatment after first chemotherapy for ovarian cancer
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT05610501Recruiting
Ultrasound-guided biopsy for pelvic masses
This study looks at how well an ultrasound-guided needle biopsy (Tru-Cut) can safely collect tissue samples from pelvic masses. It may help doctors confirm diagnoses and guide treatment by improving how biopsies are done in real-world care.
LeuvenAges 18 years+ - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT06315491RecruitingPhase 2
CBX-12 for platinum-resistant ovarian cancer
This trial tests a new drug called CBX-12 for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if CBX-12 can shrink tumors or slow the cancer down.
Scottsdale, ArizonaAges 18 years+ - NCT07280312Recruiting
Ultrasound imaging test for ovarian lesions
This trial uses a special ultrasound technique to get better images of ovarian growths before surgery. The goal is to improve detection and help plan the best treatment.
Rochester, MinnesotaAges 18 years+ - NCT04251052Recruiting
Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers
This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.
Birmingham, AlabamaAges 35–50 - NCT06817161RecruitingPhase 3
Nerve stimulation for quality of life during ovarian cancer treatment
This trial tests if a gentle nerve stimulation device on the ear can improve quality of life for people with ovarian cancer who are starting their first chemotherapy. It may help manage symptoms like fatigue or feeling sick.
CaenAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT06777082Recruiting
Study of RPL8 protein in ovarian cancer
This study looks at a protein called RPL8 in a specific type of ovarian cancer called high-grade serous ovarian carcinoma. It may help researchers understand the disease better and find new ways to treat it.
Bologna, BOAges 18 years+ - NCT05601700RecruitingPhase 3
Letrozole for low-grade ovarian cancer that uses hormones
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
Arezzo, ARAges 18 years+ - NCT06292286Recruiting
Second surgery for recurrent ovarian cancer that responds to platinum
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Hong KongAges 18 years+ - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian carcinoma?
- Yes. Clin2 currently lists 191 recruiting ovarian carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.